Page last updated: 2024-08-22

cyclacillin and ceftazidime

cyclacillin has been researched along with ceftazidime in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carter, AL; Ganapathy, ME; Ganapathy, V; Huang, W; Iseki, K; Leibach, FH; Rajan, DP; Sugawara, M1
Brandsch, M; Luckner, P1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1

Other Studies

3 other study(ies) available for cyclacillin and ceftazidime

ArticleYear
beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
    The Journal of biological chemistry, 2000, Jan-21, Volume: 275, Issue:3

    Topics: Acetylcarnitine; Animals; Anti-Bacterial Agents; Carnitine; Carrier Proteins; Cefadroxil; Cefepime; Cephaloridine; Cephalosporins; Dose-Response Relationship, Drug; HeLa Cells; Humans; Kinetics; Membrane Proteins; Nitrogen; Organic Cation Transport Proteins; Rats; Sodium; Solute Carrier Family 22 Member 5; Tumor Cells, Cultured

2000
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2005, Volume: 59, Issue:1

    Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Binding Sites; Caco-2 Cells; Dose-Response Relationship, Drug; Humans; Peptide Transporter 1; Protein Binding; Rats; Symporters

2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004